CY1118655T1 - Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης - Google Patents

Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης

Info

Publication number
CY1118655T1
CY1118655T1 CY20171100070T CY171100070T CY1118655T1 CY 1118655 T1 CY1118655 T1 CY 1118655T1 CY 20171100070 T CY20171100070 T CY 20171100070T CY 171100070 T CY171100070 T CY 171100070T CY 1118655 T1 CY1118655 T1 CY 1118655T1
Authority
CY
Cyprus
Prior art keywords
treatment
pyrimidinodiamines
athleticosis
prevention
compounds
Prior art date
Application number
CY20171100070T
Other languages
English (en)
Inventor
Esteban Masuda
Jochen Schmitz
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of CY1118655T1 publication Critical patent/CY1118655T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Περιγράφονται νέες μέθοδοι και συνθέσεις για την πρόληψη και τη θεραπεία των μορφών αθηροσκλήρωσης με ενώσεις 2,4-πυριμιδινοαμίνης. Επίσης αποκαλύπτεται η επίχριση προσθετικών συσκευών, όπως στεντ, με τις ενώσεις της εφεύρεσης για την πρόληψη και/ή θεραπεία της επαναστένωσης.
CY20171100070T 2008-02-22 2017-01-18 Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης CY1118655T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3090308P 2008-02-22 2008-02-22
PCT/US2009/034718 WO2009105675A1 (en) 2008-02-22 2009-02-20 Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
CY1118655T1 true CY1118655T1 (el) 2017-07-12

Family

ID=40559977

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100070T CY1118655T1 (el) 2008-02-22 2017-01-18 Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης

Country Status (21)

Country Link
US (1) US8530466B2 (el)
EP (1) EP2252300B1 (el)
JP (1) JP5586482B2 (el)
KR (1) KR101614555B1 (el)
CN (1) CN102014917A (el)
AU (1) AU2009215430B2 (el)
BR (1) BRPI0907724B8 (el)
CA (1) CA2715962C (el)
CY (1) CY1118655T1 (el)
DK (1) DK2252300T3 (el)
ES (1) ES2610880T3 (el)
HK (1) HK1150555A1 (el)
HR (1) HRP20170050T1 (el)
HU (1) HUE030307T2 (el)
LT (1) LT2252300T (el)
MX (1) MX2010009159A (el)
PL (1) PL2252300T3 (el)
PT (1) PT2252300T (el)
RU (1) RU2490015C2 (el)
SI (1) SI2252300T1 (el)
WO (1) WO2009105675A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
MX2012007402A (es) 2009-12-23 2012-08-23 Takeda Pharmaceutical Pirrolidinonas heteroaromaticas fusionadas como inhibidores de tirosina cinasa esplenica (syk).
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
EP2603081B1 (en) 2010-08-10 2016-10-05 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
MX2013004894A (es) 2010-11-01 2013-10-17 Celgene Avilomics Res Inc Compuestos heterociclicos y usos de los mismos.
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
KR20140006048A (ko) 2011-03-24 2014-01-15 케밀리아 에이비 신규한 피리미딘 유도체
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
BR112014001999B1 (pt) 2011-07-28 2023-11-28 Rigel Pharmaceuticals, Inc.. Composição farmacêutica sólida efervescente com alta quantidade de sal de fosfato dissódico de (6-(5-fluoro-2-(3,4,5-trimetoxifenilamino)pirimidin- 4-ilamino)-2,2-dimetil-3-oxo-2h-pirido[3,2-b][1,4]oxazin-4(3h)-il)metila, e, forma de dosagem unitária sólida
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
TR201816244T4 (tr) 2012-03-15 2018-11-21 Celgene Car Llc Epidermal büyüme faktörü reseptörü kinaz inhibitörü tuzları.
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
DK3177281T3 (da) * 2014-08-08 2024-03-11 Ali Res S R L Blanding af fedtsyrer og palmitoylethanolamid til brug i behandlingen af betændelses og allergiske patologier
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1047776C (zh) * 1993-10-01 1999-12-29 诺瓦蒂斯有限公司 具有药理学活性的吡啶类衍生物及其制备方法
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
EP1406875B1 (en) * 2001-06-26 2013-07-31 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
TW200517057A (en) * 2003-09-22 2005-06-01 Basf Ag Fungicidal mixtures
AU2005281735A1 (en) * 2004-09-10 2006-03-16 Nycomed Gmbh Ciclesonide and syk inhibitor combination and methods of use thereof
BRPI0606318B8 (pt) * 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
PL1951684T3 (pl) * 2005-11-01 2017-03-31 Targegen, Inc. Biarylowe meta-pirymidynowe inhibitory kinaz
MX2008016007A (es) * 2006-06-15 2009-01-16 Boehringer Ingelheim Int 2-anilino-4-aminoalquilenoaminopirimidinas.
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
JP5586460B2 (ja) * 2007-07-17 2014-09-10 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｐｋｃ阻害剤としての環状アミン置換ピリミジンジアミン

Also Published As

Publication number Publication date
CA2715962A1 (en) 2009-08-27
ES2610880T3 (es) 2017-05-03
SI2252300T1 (sl) 2017-04-26
DK2252300T3 (en) 2017-02-06
CN102014917A (zh) 2011-04-13
US20110046126A1 (en) 2011-02-24
JP5586482B2 (ja) 2014-09-10
BRPI0907724B1 (pt) 2019-12-17
KR20100126422A (ko) 2010-12-01
HRP20170050T1 (hr) 2017-03-10
BRPI0907724A2 (pt) 2017-06-13
AU2009215430A1 (en) 2009-08-27
JP2011513230A (ja) 2011-04-28
AU2009215430B2 (en) 2015-02-12
KR101614555B1 (ko) 2016-04-21
MX2010009159A (es) 2010-09-14
RU2490015C2 (ru) 2013-08-20
PT2252300T (pt) 2017-01-06
EP2252300B1 (en) 2016-10-19
US8530466B2 (en) 2013-09-10
HUE030307T2 (en) 2017-04-28
HK1150555A1 (zh) 2012-01-06
WO2009105675A1 (en) 2009-08-27
LT2252300T (lt) 2017-02-10
BRPI0907724B8 (pt) 2021-05-25
CA2715962C (en) 2017-03-07
EP2252300A1 (en) 2010-11-24
PL2252300T3 (pl) 2017-04-28
RU2010138899A (ru) 2012-03-27

Similar Documents

Publication Publication Date Title
CY1118655T1 (el) Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
CY1114981T1 (el) Προφαρμακα ντολουτεγκραβιρης
CY1121824T1 (el) Μεθοδοι και συνθεσεις για προληψη και ανακουφιση μυικων κραμπων και για αποκατασταση απο νευρομυικη ευερεθιστικοτητα και κοπωση μετα απο ασκηση
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
CY1119780T1 (el) Παραγωγα πυραζολινοδιονης σαν αναστολεις της οξειδασης nadph
BR112018006034A2 (pt) compostos bicíclicos como inibidores de atx
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
RS53236B (en) BETA-AMYLOIDOSIS PEPTIDES
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
EA201170832A1 (ru) Пуриновые соединения
EA201201608A1 (ru) Солнцезащитная композиция
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
ATE505191T1 (de) Ectoin zur behandlung von vascular leaks
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
MX2010010406A (es) Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CY1116802T1 (el) Ετεροκυκλικες ενωσεις
CY1113743T1 (el) Παραγωγα ισοκινολινονης ως ανταγωνιστες toy νκ3